Skip to main content
NASDAQ:AVDL

Avadel Pharmaceuticals Competitors

$8.23
-0.03 (-0.36 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.11
$8.57
50-Day Range
$7.42
$9.05
52-Week Range
$4.83
$10.32
Volume346,848 shs
Average Volume437,134 shs
Market Capitalization$481.17 million
P/E Ratio41.15
Dividend YieldN/A
Beta1.55

Competitors

Avadel Pharmaceuticals (NASDAQ:AVDL) Vs. MCRB, DCPH, MYOV, IRWD, MORF, and FPRX

Should you be buying AVDL stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Avadel Pharmaceuticals, including Seres Therapeutics (MCRB), Deciphera Pharmaceuticals (DCPH), Myovant Sciences (MYOV), Ironwood Pharmaceuticals (IRWD), Morphic (MORF), and Five Prime Therapeutics (FPRX).

Avadel Pharmaceuticals (NASDAQ:AVDL) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Avadel Pharmaceuticals and Seres Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avadel Pharmaceuticals$59.22 million8.13$-33,230,000.00($0.89)-9.25
Seres Therapeutics$34.51 million55.70$-70,280,000.00($1.20)-17.48

Avadel Pharmaceuticals has higher revenue and earnings than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Avadel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Avadel Pharmaceuticals and Seres Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avadel Pharmaceuticals00503.00
Seres Therapeutics01602.86

Avadel Pharmaceuticals currently has a consensus price target of $18.75, suggesting a potential upside of 127.83%. Seres Therapeutics has a consensus price target of $39.00, suggesting a potential upside of 85.89%. Given Avadel Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Avadel Pharmaceuticals is more favorable than Seres Therapeutics.

Institutional & Insider Ownership

53.8% of Avadel Pharmaceuticals shares are held by institutional investors. Comparatively, 94.3% of Seres Therapeutics shares are held by institutional investors. 1.4% of Avadel Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Avadel Pharmaceuticals and Seres Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avadel Pharmaceuticals38.70%-33.91%-11.75%
Seres Therapeutics-385.22%-2,867.98%-51.24%

Volatility & Risk

Avadel Pharmaceuticals has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 4.07, meaning that its stock price is 307% more volatile than the S&P 500.

Summary

Avadel Pharmaceuticals beats Seres Therapeutics on 9 of the 14 factors compared between the two stocks.

Deciphera Pharmaceuticals (NASDAQ:DCPH) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Earnings and Valuation

This table compares Deciphera Pharmaceuticals and Avadel Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Deciphera Pharmaceuticals$25 million76.54$-192,260,000.00($4.48)-7.37
Avadel Pharmaceuticals$59.22 million8.13$-33,230,000.00($0.89)-9.25

Avadel Pharmaceuticals has higher revenue and earnings than Deciphera Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Deciphera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Deciphera Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.

Institutional & Insider Ownership

73.6% of Deciphera Pharmaceuticals shares are held by institutional investors. Comparatively, 53.8% of Avadel Pharmaceuticals shares are held by institutional investors. 7.0% of Deciphera Pharmaceuticals shares are held by company insiders. Comparatively, 1.4% of Avadel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Deciphera Pharmaceuticals and Avadel Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Deciphera Pharmaceuticals01802.89
Avadel Pharmaceuticals00503.00

Deciphera Pharmaceuticals currently has a consensus target price of $73.00, suggesting a potential upside of 121.15%. Avadel Pharmaceuticals has a consensus target price of $18.75, suggesting a potential upside of 127.83%. Given Avadel Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Avadel Pharmaceuticals is more favorable than Deciphera Pharmaceuticals.

Profitability

This table compares Deciphera Pharmaceuticals and Avadel Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Deciphera PharmaceuticalsN/A-45.02%-40.12%
Avadel Pharmaceuticals38.70%-33.91%-11.75%

Summary

Avadel Pharmaceuticals beats Deciphera Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Myovant Sciences (NYSE:MYOV) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Volatility and Risk

Myovant Sciences has a beta of 2.99, suggesting that its stock price is 199% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.

Profitability

This table compares Myovant Sciences and Avadel Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Myovant SciencesN/AN/A-201.20%
Avadel Pharmaceuticals38.70%-33.91%-11.75%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Myovant Sciences and Avadel Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Myovant Sciences03302.50
Avadel Pharmaceuticals00503.00

Myovant Sciences presently has a consensus price target of $32.1667, indicating a potential upside of 55.62%. Avadel Pharmaceuticals has a consensus price target of $18.75, indicating a potential upside of 127.83%. Given Avadel Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Avadel Pharmaceuticals is more favorable than Myovant Sciences.

Valuation and Earnings

This table compares Myovant Sciences and Avadel Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myovant SciencesN/AN/A$-288,990,000.00($3.37)-6.13
Avadel Pharmaceuticals$59.22 million8.13$-33,230,000.00($0.89)-9.25

Avadel Pharmaceuticals has higher revenue and earnings than Myovant Sciences. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Myovant Sciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

33.8% of Myovant Sciences shares are held by institutional investors. Comparatively, 53.8% of Avadel Pharmaceuticals shares are held by institutional investors. 3.9% of Myovant Sciences shares are held by insiders. Comparatively, 1.4% of Avadel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Avadel Pharmaceuticals beats Myovant Sciences on 10 of the 13 factors compared between the two stocks.

Avadel Pharmaceuticals (NASDAQ:AVDL) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.

Valuation and Earnings

This table compares Avadel Pharmaceuticals and Ironwood Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avadel Pharmaceuticals$59.22 million8.13$-33,230,000.00($0.89)-9.25
Ironwood Pharmaceuticals$428.41 million4.19$21.50 million$0.5520.29

Ironwood Pharmaceuticals has higher revenue and earnings than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Avadel Pharmaceuticals has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.

Insider and Institutional Ownership

53.8% of Avadel Pharmaceuticals shares are held by institutional investors. 1.4% of Avadel Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of Ironwood Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Avadel Pharmaceuticals and Ironwood Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avadel Pharmaceuticals38.70%-33.91%-11.75%
Ironwood Pharmaceuticals27.77%-240.80%27.05%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Avadel Pharmaceuticals and Ironwood Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avadel Pharmaceuticals00503.00
Ironwood Pharmaceuticals03102.25

Avadel Pharmaceuticals currently has a consensus target price of $18.75, indicating a potential upside of 127.83%. Ironwood Pharmaceuticals has a consensus target price of $11.50, indicating a potential upside of 3.05%. Given Avadel Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Avadel Pharmaceuticals is more favorable than Ironwood Pharmaceuticals.

Summary

Avadel Pharmaceuticals beats Ironwood Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Avadel Pharmaceuticals (NASDAQ:AVDL) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Profitability

This table compares Avadel Pharmaceuticals and Morphic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avadel Pharmaceuticals38.70%-33.91%-11.75%
MorphicN/A-36.62%-20.69%

Insider & Institutional Ownership

53.8% of Avadel Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.5% of Morphic shares are owned by institutional investors. 1.4% of Avadel Pharmaceuticals shares are owned by company insiders. Comparatively, 39.5% of Morphic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Avadel Pharmaceuticals has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Morphic has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Avadel Pharmaceuticals and Morphic, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avadel Pharmaceuticals00503.00
Morphic00203.00

Avadel Pharmaceuticals currently has a consensus target price of $18.75, indicating a potential upside of 127.83%. Morphic has a consensus target price of $85.00, indicating a potential upside of 72.59%. Given Avadel Pharmaceuticals' higher possible upside, equities research analysts plainly believe Avadel Pharmaceuticals is more favorable than Morphic.

Earnings & Valuation

This table compares Avadel Pharmaceuticals and Morphic's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avadel Pharmaceuticals$59.22 million8.13$-33,230,000.00($0.89)-9.25
Morphic$16.98 million105.04$-43,330,000.00($2.69)-18.31

Avadel Pharmaceuticals has higher revenue and earnings than Morphic. Morphic is trading at a lower price-to-earnings ratio than Avadel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Avadel Pharmaceuticals beats Morphic on 10 of the 13 factors compared between the two stocks.

Five Prime Therapeutics (NASDAQ:FPRX) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Earnings and Valuation

This table compares Five Prime Therapeutics and Avadel Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Five Prime Therapeutics$14.87 million119.01$-137,200,000.00($3.92)-9.69
Avadel Pharmaceuticals$59.22 million8.13$-33,230,000.00($0.89)-9.25

Avadel Pharmaceuticals has higher revenue and earnings than Five Prime Therapeutics. Five Prime Therapeutics is trading at a lower price-to-earnings ratio than Avadel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

67.3% of Five Prime Therapeutics shares are owned by institutional investors. Comparatively, 53.8% of Avadel Pharmaceuticals shares are owned by institutional investors. 6.4% of Five Prime Therapeutics shares are owned by company insiders. Comparatively, 1.4% of Avadel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Five Prime Therapeutics and Avadel Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Five Prime Therapeutics06202.25
Avadel Pharmaceuticals00503.00

Five Prime Therapeutics currently has a consensus target price of $30.7143, suggesting a potential downside of 19.17%. Avadel Pharmaceuticals has a consensus target price of $18.75, suggesting a potential upside of 127.83%. Given Avadel Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Avadel Pharmaceuticals is more favorable than Five Prime Therapeutics.

Volatility and Risk

Five Prime Therapeutics has a beta of 4.4, meaning that its share price is 340% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.

Profitability

This table compares Five Prime Therapeutics and Avadel Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Five Prime Therapeutics-554.71%-75.84%-49.08%
Avadel Pharmaceuticals38.70%-33.91%-11.75%

Summary

Avadel Pharmaceuticals beats Five Prime Therapeutics on 10 of the 14 factors compared between the two stocks.


Avadel Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.98-6.2%$1.92 billion$34.51 million-17.93Analyst Report
Gap Down
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$33.01-1.6%$1.91 billion$25 million-6.60Analyst Report
Analyst Revision
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$20.67-4.4%$1.88 billionN/A-7.36Earnings Announcement
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$11.16-1.5%$1.80 billion$428.41 million16.17Earnings Announcement
Morphic logo
MORF
Morphic
1.5$49.25-2.7%$1.78 billion$16.98 million-31.57Analyst Report
Gap Down
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.32-2.3%$1.74 billion$26.87 million-12.73Earnings Announcement
Analyst Report
MacroGenics logo
MGNX
MacroGenics
1.4$28.94-5.6%$1.74 billion$64.19 million-9.25
Generation Bio logo
GBIO
Generation Bio
1.8$30.60-0.8%$1.73 billionN/A0.00Earnings Announcement
News Coverage
Amarin logo
AMRN
Amarin
1.6$4.35-6.0%$1.71 billion$429.76 million-86.98Analyst Downgrade
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$24.75-1.5%$1.64 billionN/A-15.18Earnings Announcement
Analyst Downgrade
Analyst Revision
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$19.74-4.8%$1.63 billionN/A0.00
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.41-6.1%$1.60 billion$145.97 million-7.05Earnings Announcement
Analyst Upgrade
Analyst Revision
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
2.0$5.32-2.3%$1.60 billion$1.63 billion12.98Earnings Announcement
Analyst Upgrade
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.6$44.30-7.0%$1.57 billionN/A0.00Earnings Announcement
Insider Selling
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.9$29.43-0.2%$1.56 billion$392.76 million12.21Analyst Revision
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$27.13-4.3%$1.54 billionN/A0.00Earnings Announcement
Cassava Sciences logo
SAVA
Cassava Sciences
1.1$37.49-4.6%$1.50 billionN/A-156.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$21.69-0.4%$1.49 billion$2.34 million-9.19Analyst Report
Gap Down
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$42.07-6.9%$1.48 billionN/A0.00Gap Down
uniQure logo
QURE
uniQure
1.7$31.97-2.6%$1.47 billion$7.28 million-8.48Earnings Announcement
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$11.29-0.5%$1.45 billion$320,000.00-7.68
Kronos Bio logo
KRON
Kronos Bio
1.7$25.43-3.7%$1.43 billionN/A0.00Earnings Announcement
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.00-1.7%$1.40 billionN/A0.00Analyst Report
Gap Up
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.26-8.7%$1.37 billionN/A-2.95
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$31.30-4.1%$1.36 billionN/A-10.54Earnings Announcement
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.5$35.81-0.9%$1.31 billionN/A-19.89Earnings Announcement
Analyst Upgrade
Analyst Revision
ImmunoGen logo
IMGN
ImmunoGen
1.5$6.56-4.7%$1.31 billion$82.27 million-16.00Earnings Announcement
Analyst Report
Gap Down
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$29.29-0.8%$1.29 billion$230,000.00-13.62Analyst Revision
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$29.60-2.1%$1.29 billion$6.20 million-12.98News Coverage
Gap Down
Zymeworks logo
ZYME
Zymeworks
1.6$27.58-2.9%$1.27 billion$29.54 million-7.32Analyst Revision
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.6$28.33-1.1%$1.27 billionN/A0.00Insider Selling
High Trading Volume
News Coverage
Endo International logo
ENDP
Endo International
1.5$5.43-5.0%$1.27 billion$2.91 billion-7.99Earnings Announcement
Analyst Revision
Innoviva logo
INVA
Innoviva
1.1$12.37-1.9%$1.25 billion$261.02 million6.31
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$18.87-1.7%$1.23 billion$73.41 million-3.99Analyst Report
Analyst Revision
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.59-2.3%$1.19 billion$59.70 million-195.90
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$32.21-2.2%$1.19 billionN/A0.00
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.38-2.4%$1.17 billion$4.23 million-8.59Analyst Revision
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$19.39-2.3%$1.17 billion$175.34 million-11.41Earnings Announcement
Shattuck Labs logo
STTK
Shattuck Labs
1.5$27.75-2.7%$1.16 billionN/A0.00Earnings Announcement
Insider Selling
High Trading Volume
News Coverage
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$21.77-2.8%$1.13 billion$4.23 million-16.13Earnings Announcement
Keros Therapeutics logo
KROS
Keros Therapeutics
1.5$48.54-4.3%$1.13 billionN/A0.00Earnings Announcement
Analyst Downgrade
Analyst Revision
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
2.0$31.15-5.5%$1.12 billion$57.05 million0.00Earnings Announcement
Gap Down
Omeros logo
OMER
Omeros
1.4$17.85-3.2%$1.11 billion$111.81 million-7.50Earnings Announcement
Analyst Downgrade
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$35.08-2.8%$1.10 billionN/A-2.51Analyst Upgrade
Gap Up
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$21.13-2.2%$1.06 billionN/A-6.95
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.6$26.04-1.3%$1.05 billion$800.40 million24.57Earnings Announcement
Zogenix logo
ZGNX
Zogenix
2.0$18.59-0.8%$1.04 billion$3.65 million-1.95Earnings Announcement
Insider Buying
Analyst Revision
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$49.91-1.5%$1.01 billion$122.47 million-27.42Earnings Announcement
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$14.73-3.9%$1.01 billionN/A-6.22
This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.